Melanotan I (MT-1)

Melanotan I, also called afamelanotide, is a synthetic version of α-MSH — the hormone the body uses to instruct pigment cells. The natural hormone is a thirteen-amino-acid chain that survives only minutes in circulation, which makes it almost useless for experiments that need a sustained signal. Melanotan I keeps the same message and changes two residues so the molecule lasts far longer.

The changes are specific and instructive. One position is swapped for a D-amino acid, the mirror-image form that protein-cutting enzymes cannot read, and another is replaced with an amino acid that stabilises the shape the receptor recognises. The result binds the same receptors as the natural hormone but is not dismantled at the same rate — a textbook demonstration of how a peptide is made durable without changing what it says.

It is also, unusually for this catalogue, a molecule with a genuine regulatory history. Afamelanotide has been approved in the European Union and the United States for a rare inherited condition in which sunlight causes severe pain, which means its pharmacology has been examined to a standard almost no research peptide reaches.

• Receptor selectivity: It acts mainly at the MC1 receptor, the melanocortin subtype found on pigment cells. Comparatively narrow receptor coverage is what separates it from Melanotan II and is usually the reason a study design specifies one rather than the other.

• Melanin synthesis pathways: Pigment cells respond to melanocortin signals by switching on the enzymes that build melanin. This is a well-mapped pathway from receptor to product, making it a clean system for studying how a hormone signal becomes a measurable output.

• Peptide stabilisation chemistry: The two substitutions that give it its long duration are a standard teaching example of how sequence changes control the working life of a peptide, and it recurs in that context in medicinal chemistry.

• Photoprotection biology: Melanin absorbs ultraviolet light, and how pigmentation relates to ultraviolet damage at the cellular level is a long-running research question. Its clinical development for a light-sensitivity disorder grew directly out of that work.

Skin colour is produced by melanocytes, cells that manufacture the pigment melanin and pass it to the surrounding skin cells. Those cells do not act on their own initiative. They carry a receptor, MC1R, and when a melanocortin hormone binds to it the cell starts the enzymatic machinery that builds pigment. This is what happens naturally on ultraviolet exposure: damage prompts the release of α-MSH, which signals the melanocytes.

Melanotan I engages that same receptor directly. The signal is the one the cell already expects, so the pathway behind it is unchanged; what differs is that the message is not cleared within minutes. That property is exactly what makes a research tool useful — a stable, repeatable stimulus that can be applied and measured, rather than a hormone that vanishes before the experiment has begun.

Melanin itself is more than a colourant. It absorbs and dissipates ultraviolet energy before that energy reaches DNA, which is why pigmentation and photodamage are studied as one subject. The compound's approved medical use rests on this: a condition in which patients experience severe pain on light exposure, where increasing pigment addresses the mechanism directly rather than the symptom.

By the standards of this catalogue the evidence is exceptionally strong. Afamelanotide has completed controlled clinical trials and carries marketing authorisation in the EU and US for erythropoietic protoporphyria. Its receptor pharmacology, duration and pigmentation effect in humans are all documented in the peer-reviewed record.

The approval covers one rare condition under medical supervision, and material supplied for research is not the pharmaceutical product; it is supplied for laboratory research only. Melanocortin signalling also reaches beyond pigment cells, so whole-organism effects are not always attributable to the MC1 pathway alone. Its research value is that it is the selective end of the melanocortin range, with pharmacology documented to a standard almost nothing else in this field reaches.

The direct comparison is Melanotan II, a shorter, cyclic analogue that is markedly less selective and engages several melanocortin receptor subtypes rather than mainly one. Where Melanotan I is the tool for asking about MC1 specifically, Melanotan II is what a study uses when the question spans the receptor family.

PT-141 completes the set as the metabolite of Melanotan II, studied at the MC4 receptor in the central nervous system. Reading the three together shows how altering one peptide scaffold moves activity from the skin to the brain, which is why they appear in the literature as a group.